Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrin sealant Kedrion is a biologic hemostatic agent developed by Kedrion S.p.A., an Italian biopharmaceutical company specializing in plasma-derived products. It is a two-component fibrin glue consisting of human plasma-derived fibrinogen and human thrombin, which are the key proteins involved in the final stage of the blood coagulation cascade. Upon application to a surgical site, thrombin converts fibrinogen into fibrin, forming a stable clot that promotes hemostasis and tissue sealing. The product has been primarily evaluated as a surgical adjunct to control intraoperative and postoperative blood loss in adult patients undergoing major or minor hepatic resection in Phase II/III clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fibrin sealant Kedrion.